Cargando…
B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009802/ http://dx.doi.org/10.1097/01.HS9.0000829572.61143.b0 |
| _version_ | 1784687342958673920 |
|---|---|
| author | Terpos, E Gavriatopoulou, M Ntanasis-Stathopoulos, I Briasoulis, A Gumeni, S Malandrakis, P Papanagnou, E-D Migkou, M Kanellias, N Kastritis, E Trougakos, I P Dimopoulos, M A |
| author_facet | Terpos, E Gavriatopoulou, M Ntanasis-Stathopoulos, I Briasoulis, A Gumeni, S Malandrakis, P Papanagnou, E-D Migkou, M Kanellias, N Kastritis, E Trougakos, I P Dimopoulos, M A |
| author_sort | Terpos, E |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9009802 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90098022022-04-18 B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA Terpos, E Gavriatopoulou, M Ntanasis-Stathopoulos, I Briasoulis, A Gumeni, S Malandrakis, P Papanagnou, E-D Migkou, M Kanellias, N Kastritis, E Trougakos, I P Dimopoulos, M A Hemasphere Best Abstracts - Oral Presentations Lippincott Williams & Wilkins 2022-04-05 /pmc/articles/PMC9009802/ http://dx.doi.org/10.1097/01.HS9.0000829572.61143.b0 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Best Abstracts - Oral Presentations Terpos, E Gavriatopoulou, M Ntanasis-Stathopoulos, I Briasoulis, A Gumeni, S Malandrakis, P Papanagnou, E-D Migkou, M Kanellias, N Kastritis, E Trougakos, I P Dimopoulos, M A B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA |
| title | B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA |
| title_full | B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA |
| title_fullStr | B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA |
| title_full_unstemmed | B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA |
| title_short | B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA |
| title_sort | b08: a third bnt162b2 dose induces antibody responses against sars-cov-2 even in previously non-responders with multiple myeloma |
| topic | Best Abstracts - Oral Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009802/ http://dx.doi.org/10.1097/01.HS9.0000829572.61143.b0 |
| work_keys_str_mv | AT terpose b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma AT gavriatopouloum b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma AT ntanasisstathopoulosi b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma AT briasoulisa b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma AT gumenis b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma AT malandrakisp b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma AT papanagnoued b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma AT migkoum b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma AT kanelliasn b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma AT kastritise b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma AT trougakosip b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma AT dimopoulosma b08athirdbnt162b2doseinducesantibodyresponsesagainstsarscov2eveninpreviouslynonresponderswithmultiplemyeloma |